Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease

Abstract

Background: Muckle-Wells syndrome (MWS) represents a moderate phenotype of cryopyrinopathies. Sensorineural hearing loss and AA amyloidosis belong to the most severe manifestations of uncontrolled disease. Simultaneous discovery of MWS in four generations of one large kindred has enabled us to document natural evolution of untreated disease and their response to targeted therapy. Methods: A retrospective case study, clinical assessment at the time of diagnosis and 2-year prospective follow-up using standardized disease assessments were combined. Results: Collaborative effort of primary care physicians and pediatric and adult specialists led to identification of 11 individuals with MWS within one family. Presence of p.Ala441Val mutation was confirmed. The mildest phenotype of young children suffering with recurrent rash surprised by normal blood tests and absence of fevers. Young adults all presented with fevers, rash, conjunctivitis, and arthralgia/arthritis with raised inflammatory markers. Two patients aged over 50 years suffered with hearing loss and AA amyloidosis. IL-1 blockade induced disease remission in all individuals while hearing mildly improved or remained stable in affected patients as did renal function in one surviving individual with amyloidosis. Conclusions: We have shown that severity of MWS symptoms gradually increased with age toward distinct generation-specific phenotypes. A uniform trajectory of disease evolution has encouraged us to postpone institution of IL-1 blockade in affected oligosymptomatic children. This report illustrates importance of close interdisciplinary collaboration.

The Efficacy of Anti-Tumor Necrosis Factor Therapy in Cryopyrin-Associated Periodic Syndromes: A Report of Two Cases

“…Our first case had severe joint disease correlated with CINCA syndrome, but CNS manifestations and mental disability were not observed. Our first case also had optic disc edema that is usually presented in CINCA syndrome [11][12][13][14][15].…”

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist

“…These signs and symptoms form the basis of evidence-based classification criteria for CAPS,48 TRAPS and MKD41 and are listed in table 2—recommendations 8 (CAPS), 10 (TRAPS), 11 (MKD) and 13 (DIRA), respectively. In combination with the molecular analyses, these features help physicians to recognise disease-specific characteristics and differentiate these conditions from clinically complex diseases that can present with overlapping inflammatory manifestations, including systemic juvenile idiopathic arthritis, adult-onset Still’s disease, neoplasms, infections and autoimmune disorders 63 64…”

“…Next-generation sequencing (NGS) platforms are now widely used and are replacing the Sanger sequencing “gene by gene” approach 51 52 66–68. NGS is therefore generally recommended 52 63 66 69 70. In certain conditions, Sanger sequencing of a single gene may be cost-effective, such as in patients with a known familial disease or classic disease features.…”

Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?

“…Impaired renal function due to AA amyloidosis in one patient remained stable as did audiometry in two patients with mild hearing loss. Two patients required dose escalation (to 200 mg/day) in order to maintain disease inactivity ( 30 ). One polymorbid adult patient died after 2 months of therapy for a pre-existing condition.…”